Clinical Trial Finder

Inclusion Criteria:

1. Age 18-85 years old. 2. Histologically confirmed esophageal cancer. 3. Patients undergoing radical resection for esophageal cancer who do not require or are not eligible for radiotherapy，T1-T4N0-3M0. 4. ECOG：0～1. 5. Expected survival ≥12 weeks. 6. Radical surgery was performed within 28 days and met R0 criteria. 7. The patient did not receive neoadjuvant radiotherapy/neoadjuvant concurrent chemoradiotherapy before surgery and no longer received adjuvant radiotherapy/adjuvant chemoradiotherapy. 8. If the major organs function normally, the following criteria are met: HB≥90g/L；b.ANC≥1.5×109/L；c.PLT ≥80×109/L；ALB≥30g/L；b.ALT和AST≤2.5ULN. 9. Women of reproductive age should agree to use contraceptives (such as Iuds, contraceptives, or condoms) during the study period and for 6 months after the study ends; Have a negative serum or urine pregnancy test within 7 days prior to study enrollment and must be a non-lactating patient; Men should consent to patients who must use contraception during the study period and for 6 months after the end of the study period. 10. The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up.

Exclusion Criteria:

1. Does not meet the above inclusion criteria. 2. Patients with distant visceral metastases. 3. Patients requiring adjuvant radiotherapy after neoadjuvant radiotherapy or radical surgery. 4. Allergic to tinidazole or metabolic disorder. 5. Patients in need of warfarin anticoagulation and those unable to abstain from alcohol. 6. Patients who do not tolerate ultrasonic dental cleaning. 7. Pregnant or lactating women. 8. Patients with other malignancies within 5 years (except cured basal cell carcinoma of the skin and cervical carcinoma in situ) 9. Patients with a history of psychotropic substance abuse who are unable to abstain or have mental disorders. 10. Patients who have participated in clinical trials of other drugs within four weeks. 11. Patients with concomitant diseases that, in the investigator's judgment, seriously endanger patient safety or interfere with the patient's completion of the study. 12. Patients with recurrent mouth ulcers or other oral diseases that affect the oral flora. 13. Patients with chronic infectious diseases or autoimmune diseases requiring prolonged or repeated use of antimicrobials or glucocorticoids. 14. The researchers did not consider it suitable for inclusion

Arms

No Intervention: Arm 1:pg（-）

The routine follow-up review after radical resection of esophageal cancer was performed according to the schedule requirements

Experimental: Arm 2:pg（+）

Dental cleaning combined with gum tape treatment every three months until disease progression/recurrence/death or intolerable adverse reactions occur.

No Intervention: Arm 3:pg（+）

The routine follow-up review after radical resection of esophageal cancer was performed according to the schedule requirements

Interventions

Combination Product: - Tinidazole oral microneedle patch

Ultrasonic teeth cleaning: After gargling with compound chlorhexidine gargle or 3% hydrogen peroxide gargle for 1 minute, the teeth were cleaned by ultrasonic wave. After the teeth were cleaned, the wound was rinsed with 3% hydrogen peroxide to stop bleeding. Immediately after the ultrasonic cleaning, two pieces of tinidazole oral composite microneedle patch were applied to the upper and lower gums close to the inside of the first molar, especially on the tooth loss or damage, and the mouth was kept closed for 15 minutes. After the microneedle was fully degraded, the room could be left.